EGFR基因突变状态对于晚期肺腺癌一线化疗的疗效预测意义.pdfVIP

·6· EGFR基因突变状态对于晚期肺腺癌 一线化疗的疗效预测意义 尹延涛王慧娟 张国伟穆艳艳马智勇 【摘要】 目的探讨表皮生长因子受体(EGFR)基因突变状态对于晚期肺腺癌一线化疗的疗效预测意义。方 法 随访郑州大学附属肿瘤医院2008年10月至2012年3月接受标准一线合铂双联化疗的IV期肺腺癌患者70 例，均经组织学确诊并进行了EGFR基因突变状态检测，其中突变型27例，野生型43例。结果突变组和野生组 d 和138 d(P=0．026)。排除后续TKI影响后两组总生存期(os)分别为426d和325d(P=0．104)。多因素分析显 突变是晚期肺腺癌一线合铂双联化疗的疗效预测因素。 【关键词】 晚期肺腺癌；表皮生长因子受体；化疗疗效；无进展生存期；总生存期 ofEGFRmutationstatusinfirst--line foradvancedade-- Prognosticsignificance chemotherapylung nocarcinomaYIN Yah—tao，WANG Guo-wei，MU Hui-jua，ZHANG Yan-yah，MaZhi一妒，增．Tumor to HospitalAffiliated 450003，China ZhengzhouUniversity，Zhengzhou To the of factorre- 【Abstract】Objectiveinvestigateprognosticsignificanceepithelialgrowth mutationstatusinfirst·line foradvanced ceptor(EGFR)gene adenocarcinoma．Meth- chemotherapy lung ods with IV adenocarcinomaadmittedintumor affiliatedto Seventypatientsstagelung hospital Zhengzhou fromOctober2008toMarch thestandardfirst·line double university 2012，who accepted platinum—based were wereall confirmedandtheEGFRmutationstatus chemotherapyfollowed·up．Theyhistologically gene Was were27casesof casesof mutant．ResultsThe detected，there genemutation，43wild-type objective ratesofmutationand mutationwere51．85％and remo— response wild—type 32．55％(P0．01)．After theeffectof 138 ofthe of ving TKI，progression—freesurvival(PFS)was days wi